EGFR and non-small cell lung carcinoma: The complexity of the mechanisms associated with acquired EGFR-TKI resistance in NSCLC has been widely demonstrated (15), and can be grouped into kinase domain mutations and overexpression of target oncogenes within tumor cells (9).